Literature DB >> 10699546

Rapid assessment and response to injecting drug use in Madras, south India.

.   

Abstract

HIV infection among injecting drug users (IDUs) is preventable, and in order to develop appropriate interventions, an assessment was carried out at Madras, South India using the Rapid Assessment and Response Guide on Injecting Drug Use developed by WHO. Data were collected with multiple methods from multiple sources using the principles of triangulation and induction. A total of 100 IDUs were interviewed. These interviews were complemented by focus groups and observations. A community advisory board ensured community ownership and participation. Findings showed that heroin, buprenorphine, diazepam and avil were the drugs most commonly injected. The use of pharmaceutical preparations as a 'cocktail' was also prevalent. Drug injectors interviewed were males, and most (81%) were from low-income groups living in slums. Direct (69%) as well as indirect sharing (94%) was common. Such unhygienic injecting practices, and the lack of access to sterile water, contribute to the high incidence of adverse health consequences. Compared with the buprenorphine injectors, heroin injectors were more likely to share injecting equipment (P=0.0022), inject more frequently (P=0.0013), have more drug using network members (P=0.0104), frequent 'shooting' locations (P=0.002), use the dealer's place to inject (P=0.0317), and face threats of arrest (P=0.0023). Many buprenorphine injectors managed their life without serious crises, and seemed to adopt a 'natural' harm reduction response. Sexual risk behaviour was prevalent among opioid users, and a history of commercial sex was associated with daily alcohol use (P=0.0221). The assessment led to an action plan which was presented and endorsed in an advocacy meeting by key stake-holders and decision-makers. The critical importance of implementing quality, accessible, community-oriented, and effective HIV interventions with the capacity to reach the majority of IDUs is discussed. Public health responses to injecting drug use must target changes among individuals at-risk, as well as in the community and risk environment.

Entities:  

Year:  2000        PMID: 10699546     DOI: 10.1016/s0955-3959(99)00057-2

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  19 in total

1.  Rapid assessment and response studies of injection drug use: knowledge gain, capacity building, and intervention development in a multisite study.

Authors:  Gerry V Stimson; Chris Fitch; Don DesJarlais; Vladimir Poznyak; Theresa Perlis; Edna Oppenheimer; Tim Rhodes
Journal:  Am J Public Health       Date:  2005-12-27       Impact factor: 9.308

2.  Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India.

Authors:  Shruti H Mehta; Darshan Sudarshi; Aylur K Srikrishnan; David D Celentano; Canjeevaram K Vasudevan; Santhanam Anand; Muniratnam Suresh Kumar; Carl Latkin; Suniti Solomon; Sunil S Solomon
Journal:  Addiction       Date:  2011-10-12       Impact factor: 6.526

3.  Alcohol use by men is a risk factor for the acquisition of sexually transmitted infections and human immunodeficiency virus from female sex workers in Mumbai, India.

Authors:  Purnima Madhivanan; Alexandra Hernandez; Alka Gogate; Ellen Stein; Steven Gregorich; Maninder Setia; Sameer Kumta; Maria Ekstrand; Meenakshi Mathur; Hema Jerajani; Christina P Lindan
Journal:  Sex Transm Dis       Date:  2005-11       Impact factor: 2.830

4.  Psychosocial Barriers to Viral Suppression in a Community-based Sample of Human Immunodeficiency Virus-infected Men Who Have Sex With Men and People Who Inject Drugs in India.

Authors:  Sandeep Prabhu; Allison M McFall; Shruti H Mehta; Aylur K Srikrishnan; Muniratnam Suresh Kumar; Santhanam Anand; Saravanan Shanmugam; David D Celentano; Gregory M Lucas; Sunil S Solomon
Journal:  Clin Infect Dis       Date:  2020-01-02       Impact factor: 9.079

5.  The profile of injection drug users in Chennai, India: identification of risk behaviours and implications for interventions.

Authors:  Sunil S Solomon; Monica Desai; A K Srikrishnan; Easter Thamburaj; C K Vasudevan; M Suresh Kumar; Suniti Solomon; David D Celentano; Shruti H Mehta
Journal:  Subst Use Misuse       Date:  2010-02       Impact factor: 2.164

6.  Emergence of cocaine and methamphetamine injection among HIV-positive injection drug users in northern and western India.

Authors:  Shruti H Mehta; Aylur K Srikrishnan; Eva Noble; Canjeevaram K Vasudevan; Suniti Solomon; M Suresh Kumar; Sunil S Solomon
Journal:  Drug Alcohol Depend       Date:  2013-12-17       Impact factor: 4.492

Review 7.  Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Authors:  Michael A Yokell; Nickolas D Zaller; Traci C Green; Josiah D Rich
Journal:  Curr Drug Abuse Rev       Date:  2011-03

8.  Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India.

Authors:  Sunil Suhas Solomon; David D Celentano; Aylur K Srikrishnan; Canjeevaram K Vasudevan; Kalilapuri G Murugavel; Syed H Iqbal; Santhanam Anand; Muniratnam Suresh Kumar; Carl Latkin; Suniti Solomon; Shruti H Mehta
Journal:  Am J Epidemiol       Date:  2010-10-08       Impact factor: 4.897

9.  High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern.

Authors:  Sunil S Solomon; Aylur K Srikrishnan; Shruti H Mehta; Conjeevaram K Vasudevan; Kailapuri G Murugavel; Easter Thamburaj; Santhanam Anand; M Suresh Kumar; Carl Latkin; Suniti Solomon; David D Celentano
Journal:  J Acquir Immune Defic Syndr       Date:  2008-11-01       Impact factor: 3.731

10.  Social and structural aspects of the overdose risk environment in St. Petersburg, Russia.

Authors:  Traci C Green; Lauretta E Grau; Ksenia N Blinnikova; Mikhail Torban; Evgeny Krupitsky; Ruslan Ilyuk; Andrei Kozlov; Robert Heimer
Journal:  Int J Drug Policy       Date:  2008-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.